Wolfgang Miesbach: Award-Winning Poster on Long-Term AAV Gene Therapy Outcomes in Hemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Delighted that this poster by Ulrike Reiss was awarded the first poster prize at EAHAD 2026 in Dublin. ‘9‑year outcomes of scAAV2/8‑LP1‑hFIXco enriched for full AAV capsids in adults with severe haemophilia B (PO041)’.
The study builds on the pioneering UCL/St Jude AAV8 haemophilia B programme, comparing a new vector prep enriched for full AAV capsids (full:empty 1:3) with the original 1:10 preparation to see whether this strategy improves FIX expression or liver safety over the long term:
FIX activity rose in the higher‑dose cohort, confirming robust liver transduction, but levels gradually declined over time instead of remaining fully stable.
Rates and patterns of vector‑associated transaminitis were similar to the earlier 1:10 study, suggesting that full‑capsid enrichment alone does not mitigate this immunogenicity signal.
Across 9 years of follow‑up there were no FIX inhibitors, no thrombotic complications and no late liver toxicity, reinforcing the long‑term safety of systemic AAV‑mediated FIX gene transfer in this cohort.
Overall, there was no clear advantage of the 1:3 full‑capsid preparation in terms of reducing transaminitis, enhancing transduction, or stabilising FIX expression compared with the original vector batch.
For me, this award‑winning poster is a great example of how meticulous vector characterisation plus truly long‑term clinical follow‑up can refine our understanding of AAV biology and guide the next generation of safer, more durablegene therapies for haemophilia B”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?